Anteris Technologies Global Corp., a structural heart company focused on developing next-generation medical devices, has secured a $90 million strategic investment from Medtronic.
The investment was completed immediately following Anteris’ underwritten public offering of common stock, together generating approximately $320 million in gross proceeds. The funds will be used to support the execution of the global pivotal PARADIGM trial and advance the company toward global commercialisation of its DurAVR Transcatheter Heart Valve (THV).
The Medtronic investment, together with the public equity offering, strengthens Anteris’ financial position as it continues the global PARADIGM trial and invests in research aimed at transforming the treatment of aortic stenosis. Wells Fargo Securities served as the sole placement agent for the Medtronic investment.
